News from newlink genetics corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jun 03, 2013, 07:30 ET NewLink Genetics Presents Results from Two Phase 1 Studies with Immunotherapy Agent, Indoximod, at the ASCO 2013 Annual Meeting

 NewLink Genetics Corporation (NASDAQ: NLNK), an oncology-focused biopharmaceutical company specializing in immunotherapy, today announced...


Jun 03, 2013, 07:30 ET NewLink Genetics' Algenpantucel-L Shows Encouraging Disease-Free and Overall Survival in Phase 2 Study in Resected Pancreatic Cancer

NewLink Genetics Corporation (NASDAQ: NLNK), an oncology-focused biopharmaceutical company specializing in immunotherapy, today announced results...


Jun 01, 2013, 09:00 ET NewLink Genetics Presents Positive Phase 2 Data on Novel Immunotherapy, Tergenpumatucel-L, in Non-Small Cell Lung Cancer at the ASCO 2013 Annual Meeting

 NewLink Genetics Corporation (NASDAQ: NLNK), an oncology-focused biopharmaceutical company specializing in immunotherapy, today announced...


May 29, 2013, 08:00 ET NewLink Genetics to Present at the Jefferies 2013 Healthcare Conference

 NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel...


Apr 25, 2013, 07:00 ET NewLink Genetics to Present at the Needham and Company 12th Annual Healthcare Conference

 NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company primarily focused on discovering, developing and commercializing...


Apr 08, 2013, 07:00 ET NewLink Genetics Presents Preclinical Data on New IDO Pathway Inhibitor, NLG919, at AACR 2013 Annual Meeting

NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company primarily focused on discovering, developing and commercializing...


Apr 04, 2013, 07:00 ET NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer

 NewLink Genetics Corporation (NASDAQ: NLNK) is a biopharmaceutical company focused on discovering, developing and commercializing cancer...


Apr 02, 2013, 07:00 ET NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer

 NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer...


Feb 25, 2013, 11:54 ET NewLink Genetics Announces Timing of Fourth Quarter and Year-End 2012 Financial Results Conference Call

 NewLink Genetics Corporation (Nasdaq:NLNK) today announced that its Fourth Quarter and fiscal year ended December 31, 2012 financial results...


Feb 04, 2013, 09:57 ET NewLink Genetics Corporation Announces Exercise of Underwriters' Option and Closing of Public Offering of Common Stock

 NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer...


Jan 30, 2013, 09:08 ET NewLink Genetics Corporation Announces Pricing of Public Offering of Common Stock

 NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer...


Jan 29, 2013, 16:16 ET NewLink Genetics Corporation Announces Proposed Public Offering of Common Stock

 NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer...


Jan 03, 2013, 07:00 ET NewLink Genetics Appoints Mr. Brian Wiley as Vice President of Business Development

 NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel...


Dec 13, 2012, 07:00 ET Clinical Data from NewLink Genetics' HyperAcute Prostate Cancer Immunotherapy Published in Journal of Immunotherapy

 NewLink Genetics Corporation (Nasdaq: NLNK) today announced that the results of a  Phase 1 dose escalation study with its proprietary...


Nov 14, 2012, 07:00 ET NewLink Genetics Receives European Orphan Designation for Algenpantucel-L Immunotherapy to Treat Pancreatic Cancer

 NewLink Genetics Corporation (Nasdaq: NLNK) today announced that the European Commission (EC) has designated HyperAcute-Pancreas®...


Nov 07, 2012, 07:00 ET Lota S. Zoth joins NewLink's Board of Directors; heads Audit Committee

 NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer...


Oct 10, 2012, 06:00 ET NewLink Genetics Launches Phase 3 Clinical Trial of algenpantucel-L Immunotherapy in Patients with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

 NewLink Genetics Corporation (Nasdaq: NLNK) announces launching of an open-label, randomized, multi-institutional Phase 3 study in patients...


Oct 03, 2012, 07:53 ET NewLink Genetics Launches Adaptive Design Phase 2B/3 Clinical Trial of tergenpumatucel-L Immunotherapy in Patients with Non-Small Cell Lung Cancer

 NewLink Genetics Corporation (Nasdaq: NLNK) announces the launching of an open-label, randomized, multi-institutional adaptive design...


Oct 02, 2012, 07:00 ET NewLink to Present at 3rd Annual Cancer Immunotherapy Conference

 NewLink Genetics (NASDAQ:NLNK) today announced that the company will be presenting at the 3rd Annual Cancer Immunotherapy: A Long-Awaited...


Jan 21, 2011, 08:00 ET NewLink Genetics to Present Phase 2 Data of Its HyperAcute® Pancreas Immunotherapy at ASCO 2011 Gastrointestinal Cancers Symposium

NewLink Genetics Corporation today announced that additional data from its Phase 2 clinical trial of the company's investigational HyperAcute®...


Jun 07, 2010, 08:00 ET NewLink Genetics to Present at Upcoming Investor Conferences

NewLink Genetics Corporation today announced that Charles Link, M.D., chairman and chief executive officer, will present at the following investor...


Jun 06, 2010, 08:00 ET NewLink Genetics' HyperAcute® Immunotherapy Phase 2 Study Shows Promise in Disease Free and Overall Survival for Resectable Pancreatic Cancer

NewLink Genetics Corporation today announced positive Phase 2 clinical trial data of its HyperAcute®-Pancreas cancer immunotherapy combined...


Apr 19, 2010, 14:00 ET NewLink Genetics Presents Positive Phase1/2 Data on HyperAcute(R)-Lung Cancer Immunotherapy

NewLink Genetics Corporation announced today data from a Phase 1/2 study showing that patients with progressive advanced non-small cell lung cancer...


Apr 15, 2010, 15:04 ET Data on NewLink Genetics' HyperAcute(R) Lung Cancer Immunotherapy to be Presented at the American Association for Cancer Research Annual Meeting

NewLink Genetics Corporation announced today that new data on its HyperAcute® lung cancer immunotherapy will be presented at a poster session...


Apr 01, 2010, 14:30 ET NewLink Genetics Takes Occupancy of New Administrative and cGMP Manufacturing Facilities

NewLink Genetics Corporation announced that it has taken occupancy of its new administrative and manufacturing facility.  The building...